Top

European Radiology

Published in:

01-05-2016 | Breast

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy

Authors: Stylianos Drisis, Thierry Metens, Michael Ignatiadis, Konstantinos Stathopoulos, Shih-Li Chao, Marc Lemort

Published in: European Radiology | Issue 5/2016

Abstract

Objectives

To assess whether DCE-MRI pharmacokinetic (PK) parameters obtained before and during chemotherapy can predict pathological complete response (pCR) differently for different breast cancer groups.

Methods

Eighty-four patients who received neoadjuvant chemotherapy for locally advanced breast cancer were retrospectively included. All patients underwent two DCE-MRI examinations, one before (EX1) and one during treatment (EX2). Tumours were classified into different breast cancer groups, namely triple negative (TNBC), HER2+ and ER+/HER2−, and compared with the whole population (WP). PK parameters Ktrans and Ve were extracted using a two-compartment Tofts model.

Results

At EX1, Ktrans predicted pCR for WP and TNBC. At EX2, maximum diameter (Dmax) predicted pCR for WP and ER+/HER2−. Both PK parameters predicted pCR in WP and TNBC and only Ktrans for the HER2+. pCR was predicted from relative difference (EX1 − EX2)/EX1 of Dmax and both PK parameters in the WP group and only for Ve in the TNBC group. No PK parameter could predict response for ER+/HER−. ROC comparison between WP and breast cancer groups showed higher but not statistically significant values for TNBC for the prediction of pCR

Conclusions

Quantitative DCE-MRI can better predict pCR after neoadjuvant treatment for TNBC but not for the ER+/HER2− group.

Key Points

• DCE-MRI-derived pharmacokinetic parameters can predict response status of neoadjuvant chemotherapy treatment.

• Ktrans can better predict pCR for the triple negative group.

• No pharmacokinetic parameter could predict response for the ER+/HER2− group.

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed

Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al (2003) Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843–850CrossRefPubMed

Von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685CrossRef

Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949CrossRefPubMed

Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456–1466CrossRefPubMed

von Minckwitz G, Kummel S, Vogel P et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542–551CrossRef

Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983–5992CrossRefPubMed

Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800CrossRefPubMed

Von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804CrossRef

10.

Ignatiadis M, Singhal SK, Desmedt C et al (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30:1996–2004CrossRefPubMed

11.

Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361–374CrossRefPubMed

12.

Marinovich ML, Sardanelli F, Ciatto S et al (2012) Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast 21:669–773CrossRefPubMed

13.

Ah-See M, Makris A, Taylor NJ et al (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14:6580–6589CrossRefPubMed

14.

Tofts PS, Berkowitz B, Schnall M (1995) Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33:564–568CrossRefPubMed

15.

Deoni SC, Peters TM, Rutt BK (2004) Determination of optimal angles for variable nutation proton magnetic spin-lattice, T1, and spin-spin, T2, relaxation times measurement. Magn Reson Med 51:194–199CrossRefPubMed

16.

Buckley DL, Kerslake RW, Blackband SJ et al (1994) Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR imaging using an automated simplex minimization procedure. Magn Reson Med 32:646–651CrossRefPubMed

17.

Knopp MV et al (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260–266CrossRefPubMed

18.

Weinmann J, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16:167–172PubMed

19.

Bear HD, Anderson S, Brown A (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165–4174CrossRefPubMed

20.

Rouzier R, Perou CM, Fraser Symmans W et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685CrossRefPubMed

21.

Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed

22.

Leake R, Barnes D, Pinder S et al (2000) Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 53:634–635CrossRefPubMedPubMedCentral

23.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed

24.

Swets JA (1996) Signal detection theory and ROC analysis in psychology and diagnostics: collected papers. Lawrence Erlbaum Associates, Mahwah

25.

Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843CrossRefPubMed

26.

Loo CE, Straver ME (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660–666CrossRefPubMed

27.

McGuire KP, Toro-Burguete J, Dang H et al (2011) MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18:3149–3154CrossRefPubMed

28.

Nakahara H, Yasuda Y, Machida E et al (2011) MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer 18:152–160CrossRefPubMed

29.

Li SP, Padhani AR, Taylor NJ et al (2011) Vascular characterisation of triple negative breast carcinomas using dynamic. MRI Eur Radiol 21:1364–1373CrossRefPubMed

30.

Koo HR, Cho N, Song IC, Kim H et al (2012) Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers. J Magn Reson Imaging 36:145–151CrossRefPubMed

31.

Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA et al (2011) Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 24:774–785CrossRefPubMed

32.

Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvasular proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835CrossRefPubMed

33.

Linderholm BK, Hellborg H, Johansson U et al (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20:1639–1646CrossRefPubMed

34.

Linderholm BK, Lindahl T, Holmberg L et al (2001) The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61:5407–5414

35.

Greenberg A, Rugo HS (2010) Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 16:33–38CrossRefPubMed

36.

Baek HM, Chen JH, Nie K et al (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251:653–662CrossRefPubMedPubMedCentral

37.

Manton DJ, Chaturvedi A, Hubbard A et al (2006) Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94:427–435CrossRefPubMedPubMedCentral

38.

Henderson E, Rutt BK, Lee TY (1998) Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 16:1057–1073CrossRefPubMed

39.

Heisen M, Fan X, Buurman J et al (2010) The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magn Reson Med 63:811–816CrossRefPubMedPubMedCentral

40.

Johansen R, Jensen LR, Rydland J et al (2009) Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Res Imaging 29:1300–1307CrossRef

41.

Chang YC, Huang CS et al (2004) Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol 49:3593–3602CrossRefPubMed

42.

Loo CE, Teertstra HJ, Rodenhuis S et al (2008) Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 191:1331–1338CrossRefPubMed

43.

Jacobs MA, Stearns V, Wolff AC et al (2010) Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol 17:1477–1485CrossRefPubMedPubMedCentral

Title: Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy
Authors: Stylianos Drisis
Thierry Metens
Michael Ignatiadis
Konstantinos Stathopoulos
Shih-Li Chao
Marc Lemort
Publication date: 01-05-2016
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 5/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3948-0

At a glance: The STEP trials

Springer Medicine

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 5/2016

Non-invasive MR assessment of macroscopic and microscopic vascular abnormalities in the rectal tumour-surrounding mesorectum

Cerebrospinal fluid volumetric MRI mapping as a simple measurement for evaluating brain atrophy

Diffusion-weighted MR imaging of metastatic abdominal and pelvic tumours is sensitive to early changes induced by a VEGF inhibitor using alternative diffusion attenuation models

Assessment of normal left atrial appendage anatomy and function over gender and ages by dynamic cardiac CT

Ultrasound guidance to perform intra-articular injection of gadolinium-based contrast material for magnetic resonance arthrography as an alternative to fluoroscopy: the time is now

Technical feasibility and validation of a coronary artery calcium scoring system using CT coronary angiography images